Biosense Webster Launches the OCTARAY ™ Mapping Catheter with TRUEref™ Technology

IRVINE, CA – September 6, 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than PENTARAYTM NAV ECO Mapping Catheter, which may shorten overall ablation procedure times.[2],[8],[‡] AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide.[1] AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.[2],[3] Catheter ablation is a safe and effective procedure to restore the heart’s incorrect electrical signals, which causes an abnormal heart rhythm.[4] The OCTARAY™ Mapping Catheter can map arrhythmias in any chamber and provides physicians with enhanced clarity, speed and integration to quickly capture precise information for their catheter ablation procedures.[1],[2],[‡] “With more splines and electrodes, the increased surface area coverage and improved signal quality with the OCTARAY™ Mapping Catheter allows me to better understand the anatomy and conduction properties of the chamber of interest,” said Dr. Amit Thosani, Director of Ca...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news